Circulating MicroRNA Expression Profiles in Patients with Stable and Unstable Angina

Liu, Sudong; Guo, Xiaohong; Zhong, Wei; Weng, Ruiqiang; Liu, Jing; Gu, Xiaodong; Zhong, Zhixiong

doi:10.6061/clinics/2020/e1546

Cited by 6 publications

(4 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With regard to the subtype of MI, Ward et al reported that miR-25-3p, miR-221-3p, and miR-374b-5p were strongly correlated with ST-Elevation Myocardial Infarction (STEMI), while miRs-221-3p and -483-5p were highly associated with non-ST-Elevation Myocardial Infarction (NSTEMI) [ 135 ]. The upregulation of a few other miRNAs (miR-134, miR-198, and miR-370) was uniquely linked to unstable angina (UA) compared to stable CAD, and can facilitate the diagnosis of UA, which can be elusive in some patients with normal troponin values [ 136 ].…”

Section: The Clinical Implementation Of the Biomarker Mirna Network I...mentioning

confidence: 99%

Dissecting miRNA–Gene Networks to Map Clinical Utility Roads of Pharmacogenomics-Guided Therapeutic Decisions in Cardiovascular Precision Medicine

Chatzopoulou

Kyritsis

Papagiannopoulos

et al. 2022

Cells

View full text Add to dashboard Cite

MicroRNAs (miRNAs) create systems networks and gene-expression circuits through molecular signaling and cell interactions that contribute to health imbalance and the emergence of cardiovascular disorders (CVDs). Because the clinical phenotypes of CVD patients present a diversity in their pathophysiology and heterogeneity at the molecular level, it is essential to establish genomic signatures to delineate multifactorial correlations, and to unveil the variability seen in therapeutic intervention outcomes. The clinically validated miRNA biomarkers, along with the relevant SNPs identified, have to be suitably implemented in the clinical setting in order to enhance patient stratification capacity, to contribute to a better understanding of the underlying pathophysiological mechanisms, to guide the selection of innovative therapeutic schemes, and to identify innovative drugs and delivery systems. In this article, the miRNA–gene networks and the genomic signatures resulting from the SNPs will be analyzed as a method of highlighting specific gene-signaling circuits as sources of molecular knowledge which is relevant to CVDs. In concordance with this concept, and as a case study, the design of the clinical trial GESS (NCT03150680) is referenced. The latter is presented in a manner to provide a direction for the improvement of the implementation of pharmacogenomics and precision cardiovascular medicine trials.

show abstract

Section: The Clinical Implementation Of the Biomarker Mirna Network I...mentioning

confidence: 99%

Dissecting miRNA–Gene Networks to Map Clinical Utility Roads of Pharmacogenomics-Guided Therapeutic Decisions in Cardiovascular Precision Medicine

Chatzopoulou

Kyritsis

Papagiannopoulos

et al. 2022

Cells

View full text Add to dashboard Cite

show abstract

“…There were no statistically significant variations in age or sex between the UA and control groups, according to another research [19].…”

Section: Discussionmentioning

confidence: 73%

Role of MicroRNA-1 as Diagnostic and Differentiating Biomarker between Acute Anterior Myocardial Infarction and Unstable Angina

M. Abd El khalek,

M. El Bermawy,

A. Mansour

et al. 2024

Benha Journal of Applied Sciences

View full text Add to dashboard Cite

Worldwide, coronary artery disease (CAD) accounts for a disproportionate share of all cardiovascular deaths. Disruption of the atherosclerotic plaque and thrombotic blockage of the artery cause acute coronary syndrome (ACS), a subtype of coronary artery disease (CAD). Acute anterior myocardial infarction (MI) and unstable angina (UA) are disorders that are part of acute coronary syndrome (ACS). These diseases indicate myocardial damage and necrosis. Assessment of symptoms, changes in troponin, and electrocardiogram (ECG) abnormalities due to ischemia are the current clinical diagnostic tools for acute coronary syndrome (ACS). On the other hand, "classic" symptoms are rare and don't reliably differentiate between cardiac and noncardiac reasons of chest discomfort in certain groups, such as diabetics, women, and the elderly. Ultimately, miR-1 enhances myoblast development by targeting the production of heat shock proteins (HSP)-60, HSP-70, and Bcl-2. It is secreted into the bloodstream after cardiac damage and is strongly expressed in skeletal muscle and cardiomyocytes. Its promise for quick diagnosis is supported by the fact that its level rises in plasma samples taken from patients shortly after symptoms begin. A number of diseases and conditions, including cardiovascular disease, have miRNAs in circulation as potential non-invasive indicators (CVD) The goal of this study was to identify if microRNA-1 could be utilised as a tool for discriminating between unstable angina (UA) and acute anterior myocardial infarction (MI), as well as to evaluate the impact of microRNA-1 expression in the diagnosis of UA and MI in patients (UA).

show abstract

“…Liu et al [ 37 ] reported that different miRNAs are upregulated both in stable and unstable angina (UA) compared with subjects with normal coronary arteries; in particular, they suggest that these circulating miRNAs could be used as potential biomarkers of UA. Ling et al [ 36 ] reported that miR-21 (less expressed compared with controls) and miR-126 (more expressed compared to controls) could be useful markers for predicting AMI and UA.…”

Section: Resultsmentioning

confidence: 99%

miRNA Dysregulation in Cardiovascular Diseases: Current Opinion and Future Perspectives

Sessa

Salerno

Esposito

et al. 2023

IJMS

View full text Add to dashboard Cite

MicroRNAs (miRNAs), small noncoding RNAs, are post-transcriptional gene regulators that can promote the degradation or decay of coding mRNAs, regulating protein synthesis. Many experimental studies have contributed to clarifying the functions of several miRNAs involved in regulatory processes at the cardiac level, playing a pivotal role in cardiovascular disease (CVD). This review aims to provide an up-to-date overview, with a focus on the past 5 years, of experimental studies on human samples to present a clear background of the latest advances to summarize the current knowledge and future perspectives. SCOPUS and Web of Science were searched using the following keywords: (miRNA or microRNA) AND (cardiovascular diseases); AND (myocardial infarction); AND (heart damage); AND (heart failure), including studies published from 1 January 2018 to 31 December 2022. After an accurate evaluation, 59 articles were included in the present systematic review. While it is clear that miRNAs are powerful gene regulators, all the underlying mechanisms remain unclear. The need for up-to-date data always justifies the enormous amount of scientific work to increasingly highlight their pathways. Given the importance of CVDs, miRNAs could be important both as diagnostic and therapeutic (theranostic) tools. In this context, the discovery of “TheranoMIRNAs” could be decisive in the near future. The definition of well-setout studies is necessary to provide further evidence in this challenging field.

show abstract

Circulating MicroRNA Expression Profiles in Patients with Stable and Unstable Angina

Cited by 6 publications

References 44 publications

Dissecting miRNA–Gene Networks to Map Clinical Utility Roads of Pharmacogenomics-Guided Therapeutic Decisions in Cardiovascular Precision Medicine

Dissecting miRNA–Gene Networks to Map Clinical Utility Roads of Pharmacogenomics-Guided Therapeutic Decisions in Cardiovascular Precision Medicine

Role of MicroRNA-1 as Diagnostic and Differentiating Biomarker between Acute Anterior Myocardial Infarction and Unstable Angina

miRNA Dysregulation in Cardiovascular Diseases: Current Opinion and Future Perspectives

Contact Info

Product

Resources

About